+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Genetic cancer vaccines: current status and perspectives

Genetic cancer vaccines: current status and perspectives

Expert Opinion on Biological Therapy 12(8): 1043-1058

The recent approval of the first therapeutic cancer vaccine by the US Regulatory Agency represents a breakthrough event in the history of cancer treatment. The past scepticism towards this type of therapeutic intervention is now replaced by great expectations. The field is now moving towards the development of alternative vaccination technologies, which are capable of generating stronger, more durable and efficient immune responses against specific tumour-associated antigens (TAAs) in combination with cheaper and more standardised manufacturing. In this context, genetic vaccines are emerging among the most promising methodologies. Several evidences point to combinations of different genetic immunisation modalities (heterologous prime/boost) as a powerful approach to induce superior immune responses and achieve greater clinical efficacy. In this review, we provide an overview of the current status of development of genetic cancer vaccines with particular emphasis on adenoviral vector prime/DNA boost vaccination schedules. We believe that therapeutic genetic cancer vaccines have the strong potential to become an established therapeutic modality for cancer in next coming years, in a manner similar to what have now become monoclonal antibodies.

(PDF emailed within 0-6 h: $19.90)

Accession: 053379817

Download citation: RISBibTeXText

PMID: 22577875

DOI: 10.1517/14712598.2012.689279

Related references

Current status and perspectives on protein-based pneumococcal vaccines. Critical Reviews in Microbiology 41(2): 190-200, 2016

Vaccines against human diarrheal pathogens: current status and perspectives. Human Vaccines & Immunotherapeutics 10(6): 1522-1535, 2015

Swine influenza vaccines: current status and future perspectives. Animal Health Research Reviews 11(1): 81-96, 2010

Lactococcus lactis-based vaccines: current status and future perspectives. Human Vaccines 7(1): 106-109, 2011

Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives. Anales del Sistema Sanitario de Navarra 32(1): 61-73, 2009

Development of vaccines against human parasitic diseases: tools, current status and perspectives. Expert Opinion on Investigational Drugs 9(2): 301-310, 2000

Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV). Plant Cell Reports 31(3): 495-511, 2013

Current status of viral expression systems in plants and perspectives for oral vaccines development. Plant Molecular Biology 87(3): 203-217, 2015

Current perspectives in prostate cancer vaccines. Anti-Cancer Agents in Medicinal Chemistry 9(10): 1052-1057, 2010

Cancer vaccines: current directions and perspectives in prostate cancer. Current Opinion in Molecular Therapeutics 11(1): 31-36, 2009

Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses. Acta Tropica, 2018

Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I. Clinical Oncology ) 16(5): 356-365, 2004

The current status of cancer vaccines. Einstein Quarterly Journal of Biology & Medicine 15(1): 3-23, 1998

Genetic engineering of seaweeds: current status and perspectives. Proceedings of the 17th International Seaweed Symposium, Cape Town, South Africa, 28 January 2 February 2001: 19-26, 2003

Current status of foot-and-mouth disease vaccines including the use of genetic engineering. Australian Veterinary Journal 60(5): 129-135, 1983